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EZH2 is the catalytic subunit of polycomb repressive complex 2 (PRC2), which generates
a methylation epigenetic mark at lysine 27 residue of histone H3 (H3K27me3) to silence
gene expression. EZH2 target genes are involved in a variety of biological processes such
as stem cell pluripotency, cell proliferation, and oncogenic transformation. EZH2 is often
over-expressed in epithelial ovarian cancer (EOC) cells and in ovarian cancer-associated
stromal endothelial cells. Notably, EZH2 promotes cell proliferation, inhibits apoptosis and
enhances angiogenesis in EOCs. In contrast to genetic alterations, which are typically
non-reversible, epigenetic alterations are reversible. Thus, inhibiting EZH2/PRC2 activity
represents an attractive strategy for developing ovarian cancer therapeutics by target-
ing both ovarian cancer cells and ovarian tumor microenvironment. Here we discuss the
progress recently obtained in understanding how EZH2/PRC2 promotes malignant phe-
notypes of EOC. In addition, we focus on strategies for targeting EZH2/PRC2 to develop
novel EOC epigenetic therapeutics.
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Epithelial ovarian cancer (EOC) accounts for more death than any
other gynecological malignancies in the developed world (Amer-
ican Cancer Society, 2012). Thus, there is an urgent need to
understand the etiology and biology of the disease to develop new
therapeutics. EZH2 catalyzes lysine 27 methylation on histone H3
to epigenetically silence the expression of its target genes (Bracken
et al., 2006). EZH2 by itself is catalytically inactive and has to com-
plex with other components of polycomb repressive complex 2
(PRC2) to exert its enzymatic activity (Cao and Zhang, 2004; Ketel
et al., 2005). At minimum, it requires SUZ12 and EED subunits,
while RbAp48 subunit can further boost the methyltransferase
activity of EZH2 (Cao and Zhang, 2004). PRC2/EZH2 target genes
are highly enriched for pathways that regulate stem cell pluripo-
tency, cell proliferation, and oncogenic transformation (Kleer
et al., 2003; Ting et al., 2006; Jones and Baylin, 2007; Schwartz and
Pirrotta, 2007; Jaenisch and Young, 2008; Li et al., 2012a). Not sur-
prisingly, components of PRC2 are often over-expressed in human
cancers and their expression often positively correlates with aggres-
siveness in these diseases (Varambally et al., 2002; Kleer et al., 2003;
Li et al., 2010, 2012b). In addition, gain-of-function mutations in
EZH2 have also been reported in certain hematopoietic malig-
nancies (Ryan et al., 2011; Majer et al., 2012). Notably, it has been
shown that EZH2 and other components of PRC2 play a key role in
regulating proliferation, apoptosis, and invasion of human EOC
cells (Li et al., 2010, 2012b; Lu et al., 2010). In addition, EZH2
regulates EOC microenvironment by enhancing angiogenesis (Lu
et al., 2010). Significantly, highly specific small molecule inhibitors
of EZH2 methyltransferase activity have recently been developed
(Knutson et al., 2012; McCabe et al., 2012b; Qi et al., 2012). Here
we will discuss latest advances in understanding the biological
function and regulation of EZH2/PRC2 in EOC as well as the
therapeutic targeting EZH2/PCR2 in this devastating disease.
EXPRESSION AND REGULATION OF EZH2/PRC2
EZH2, when presents in PRC2, can add up to three methyl groups
to the lysine 27 of histone H3 (H3K27Me3) via its SET domain
methyltransferase (Bracken et al., 2006). EZH2 is often over-
expressed in human EOC cells compared with normal human
ovarian surface epithelial cell (Li et al., 2010). In addition, there is
recent evidence to suggest that a proportion of high-grade serous
EOC may arise from distal fallopian tube epithelial cells (Levanon
et al., 2008; Kurman and Shih, 2010; Kuhn et al., 2012). Notably,
compared with normal fallopian tube epithelium, EZH2 is over-
expressed in high-grade serous EOC (Li et al., 2012b). Likewise,
other components of PRC2 such as SUZ12 are also over-expressed
in EOC compared with either normal human ovarian surface
epithelial cells or fallopian tube epithelial cells (Li et al., 2012b).
Indeed, the expression of EZH2 and SUZ12 positively correlates
with each other in human EOCs, further supporting the idea that
EZH2 functions within PRC2 in EOC (Li et al., 2012b).
Interestingly, although EZH2 upregulation correlates with an
increased level of H3K27Me3 in EOC cell lines (Li et al., 2010),
there is evidence to suggest that EZH2 levels do not correlate
with H3K27Me3 levels in primary EOC specimens (Wei et al.,
2008). There are a number of possible reasons for this phenom-
enon. First, although the core subunits of PRC2 such as EZH2,
SUZ12, and EED are over-expressed in EOC cells (Li et al., 2010,
2012b), the expression of other PRC2 associated proteins such as
RbAp48 and AEBP2 can also affect the methyltransferase activ-
ity of EZH2 and/or the recruitment of PRC2 to its target genes
(Cao and Zhang, 2004). For example, in vitro histone methyl-
transferase assay showed that addition of RbAp48 to EZH2–EED–
SUZ12 complex or AEBP2 to the EZH2–EED–SUZ12–RbAp48
complex significantly increased the methyltransferase activity of
PRC2 (Cao and Zhang, 2004). In addition, it was recently found
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that polycomb-like (PCL) family proteins such as PHF19 play a
critical role in the recruitment of PRC2/EZH2 to its target genes
(Ballare et al., 2012). Biochemically, C-terminal end of PHF19
binds to SUZ12 in the context of an intact PRC2 (Ballare et al.,
2012). Knockdown of PHF19 did not affect the stability of the
PRC2 complex, but the association of PRC2 with the promoters
of target genes was substantially reduced and, consequently, vast
majority of target genes lost their H3K27Me3 epigenetic mark
(Ballare et al., 2012). Likewise, JARID2 is also important for the
recruitment of PRC2 to its target genes (Landeira et al., 2010).
Together, these findings demonstrated that a stable association of
PRC2 at target genes is required for its gene silencing function
and PRC2 associated proteins play a key role in regulating the
recruitment of PRC2 to its target genes. Another class of regula-
tors of PRC2’s genomic localization is non-coding RNAs such as
HOTAIR (Tsai et al., 2010), XIST (Zhao et al., 2008), and intronic
RNAs (Guil et al., 2012). They bind directly to PRC2 to regulate its
association with target genes. Finally, histone demethylases such as
UTX and JMJD3 can decrease the levels of H3K27Me3 (Agger et al.,
2007) and loss of function mutations in UTX have been reported
in human cancers (Gui et al., 2011; Jankowska et al., 2011). Thus,
it will be interesting to examine the correlation between expres-
sion of core subunits of PRC2 and expression of PRC2 associated
proteins, non-coding RNAs and histone demethylases in EOC.
In addition to over-expression, gain-of-function EZH2 muta-
tions have been reported in hematopoietic malignancies (Ryan
et al., 2011; Majer et al., 2012). The most common mutations
occur within the SET domain that confers methyltransferase activ-
ity. For example, Y641 mutations have been identified in ∼20%
of germinal-center diffuse large B-cell lymphomas and in ∼7%
of follicular lymphomas (Bodor et al., 2011). Interestingly, these
mutations are always heterozygous and the resulting cells also car-
ries a wild type copy of EZH2 (Morin et al., 2010; Sneeringer
et al., 2010). Mechanistically, the mutant EZH2 exhibits little to
no activity for H3K27Me0 substrate and a decreased activity for
H3K27Me1 substrate, while display significantly increased activity
for H3K27Me2 substrate (Sneeringer et al., 2010). Consequently,
the wild type EZH2 retained in these cells accounts for the genera-
tion of H3K27Me1 and H2K27Me2, which led to a global increase
in H3K27Me3 by the mutant EZH2 in these tumor cells. Notably,
A677 mutations in the EZH2’s SET domain also occur in human
lymphoma albeit at much lower rate compared with Y641, which
exhibits an increased enzymatic activity independent of H3K27
methylation status (McCabe et al., 2012a). This led to a global
increase in H3K27Me3 levels (McCabe et al., 2012a). Regardless,
EZH2 mutation has not been reported in EOC and there is no
evidence of EZH2 mutation in EOCs based on the newly released
The Cancer Genome Atlas (TCGA) EOC database.
In response to intrinsic and extrinsic cues, EZH2 activity is
regulated by post-translation modification such as phosphory-
lation. For example, T350 residue of EZH2 is subject to cyclin-
dependent kinases (CDK) 1 and 2 during S and G2/M phases
of the cell cycle, respectively (Chen et al., 2010). T350 phospho-
rylation enhances PRC2/EZH2-mediated gene silencing through
increasing the recruitment of PRC2 to its target genes, while has
no effect on PRC2 complex assembly or EZH2 enzymatic activity
(Chen et al., 2010). Thus, this mechanism links intrinsic cell cycle
progression to EZH2 function. In addition, extracellular cues can
also affect EZH2 function by signaling activated kinases such as
AKT (Cha et al., 2005) and p38 (Palacios et al., 2010). S21 residue
of EZH2 can be phosphorylated by AKT, which decreases histone
methylation by PRC2 (Cha et al., 2005). Interestingly, recent evi-
dence suggests that phosphorylation of EZH2 by AKT at S21 site
leads to PRC2-independent association of EZH2 with androgen
receptor and activation of its target genes in prostate cancer cells
(Xu et al., 2012). Given that AKT is often hyperactive in EOC
(Altomare et al., 2004), it is possible that AKT directly regulates
EZH2 in a PRC2-independent manner to activate certain genes
in EOC. In addition, in skeletal muscle stem cells, stress response
kinase p38 alpha phosphorylates T372 residue of EZH2 in response
to exposure to TNF inflammatory cytokine (Palacios et al., 2010).
This leads to an enhanced repression of PRC2 target skeletal mus-
cle stem cell marker to promote cell differentiation. Notably, the
relevance of these post-translation phosphorylation modifications
in EOC remains to be determined.
ROLE OF EZH2/PRC2 IN EOC
Components of PRC2 are often over-expressed in human EOC
cells and their expression positively correlates with markers of
cell proliferation such as Ki67 (Li et al., 2010, 2012b). Signif-
icantly, higher levels of EZH2 (Lu et al., 2010) or SUZ12 (Li
et al., 2012b) expression predict shorter overall survival in EOC
patients. Indeed, knockdown of EZH2 (Li et al., 2010) or SUZ12
(Li et al., 2012b) suppresses the growth of human EOC cells in vitro
and in vivo in both subcutaneous and orthotopic xenograft EOC
models in immunocompromised mice. This is due to induction
of programed cell death or apoptosis (Li et al., 2010, 2012b). In
addition, knockdown of EZH2 suppresses the invasion of human
EOC cells (Li et al., 2010; Lu et al., 2010; Rao et al., 2010), which
correlates with a decrease in transforming growth factor-beta 1
(TGF β1) expression and an increase in E-cadherin expression
(Rao et al., 2010). These observed phenotypes correlate with a
decrease in the levels of H3K27Me3 in these cells (Rao et al.,
2010). Together, these findings are consistent with the notion that
EZH2/PRC2 promotes EOC by suppressing cell apoptosis (Li et al.,
2010, 2012b) and increasing their invasion potential (Li et al., 2010;
Rao et al., 2010) by silencing its target genes through H3K27Me3
epigenetic mark.
Notably, EZH2 expression is upregulated in ovarian cancer stem
cell-like cells enriched by chemotherapy (Rizzo et al., 2011) and
knockdown of EZH2 leads to loss of stem cell-like properties in
these cells (Rizzo et al., 2011), such as anchorage-independent
growth and tumor growth in xenograft mouse model. Similarly,
it has been demonstrated that compared with cisplatin sensitive
parental EOC cells, EZH2 expression is upregulated in in vitro
derived cisplatin-resistant EOC cells (Hu et al., 2010). Conversely,
knockdown of EZH2 re-sensitized drug-resistant ovarian cancer
cells to cisplatin (Hu et al., 2010). Together, these reports sup-
port the idea that EZH2 may contribute to chemoresistance by
regulating stem-like cell population in EOCs.
Interestingly, EZH2 is also over-expressed in EOC-associated
endothelial cells due to a direct paracrine VEGF stimulation (Lu
et al., 2010) and EZH2 promotes angiogenesis by silencing vaso-
hibin1 (VASH1) (Lu et al., 2010). Consistently, EZH2 knockdown
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in the EOC-associated endothelial cells inhibits angiogenesis and
reduces EOC growth, which is further enhanced by EZH2 knock-
down in EOC cells (Lu et al., 2010). Thus, EZH2 also contributes
to malignant behaviors of EOC by altering EOC-associated tumor
microenvironment through promoting angiogenesis. Notably,
recent anti-angiogenesis clinical trials by targeting VEGF demon-
strated potential benefit when added to standard chemotherapy in
the first-line treatment of ovarian cancer (Burger et al., 2011; Per-
ren et al., 2011). Together, these observations suggest that EZH2
is a potential target for designing new anti-angiogenesis therapy
in EOC.
Genome-wide chromatin immunoprecipitation followed by
deep sequencing analysis and gene expression profile reveal that
the number of genes upregulated upon EZH2 knockdown is sig-
nificantly lower than the number of genes whose genomic loci
are directly occupied by EZH2/H3K27Me3 (Li et al., 2012a). This
is consistent with the observation that histone deacetylase (Van
der Vlag and Otte, 1999) and DNA methylation (Nakamura et al.,
2008) also regulate the expression of EZH2 target genes. In addi-
tion to VASH1, the cellular networks enriched by EZH2 target
genes in EOC cells include cell death, growth and proliferation and
reproductive system development, and cancer (Li et al., 2012a).
These findings further support EZH2’s proliferation-promoting
and apoptosis-suppressing function. Notably, Harakiri (HRK),
a proapoptotic gene, is subjected to H3K27Me3 mediated gene
silencing in EOC cells and HRK plays a key role in regulating
apoptosis induced by suppressing H3K27Me3 (Li et al., 2012b).
HRK is also subjected to DNA methylation (Nakamura et al.,
2008) mediated gene silencing, further suggesting possible coop-
eration between H3K27Me3 and DNA methylation mediated gene
silencing.
THERAPEUTIC TARGETING EZH2/PRC2 IN EOC
In contrast to genetic changes that are non-reversible, epigenetic
alterations are reversible. This feature makes epigenetic alterations
in cancer an ideal target for developing cancer therapeutics (Daw-
son and Kouzarides, 2012). Significantly, EZH2 is over-expressed
in both EOC cells and EOC-associated endothelial cells and its
knockdown suppresses EOC growth (Li et al., 2010; Lu et al.,
2010). These observed effects correlate with a decrease in levels
of H3K27Me3, the enzymatic product of EZH2 methyltransferase
(Li et al., 2010; Lu et al., 2010). Together, these findings strongly
suggest that EZH2’s methyltransferase activity is a potential target
for developing urgently needed EOC therapeutics.
The first reported inhibitor of EZH2’s methyltransferase activ-
ity is DZNep, an inhibitor of S-adenosylhomocysteine (SAH)
hydrolase (Tan et al., 2007). However, DZNep indirectly inhibits
EZH2 activity by causing the degradation of components of
PRC2 through increasing the cellular levels of SAH, the inhibitory
byproduct of methyltransferase reaction (Tan et al., 2007). In addi-
tion, DZNep is non-specific with major effects on a number of
other histone methyl marks and, consequently, has been shown to
be very toxic (Miranda et al., 2009). In contrast, a number of new
specific EZH2 methyltransferase inhibitors have been reported
very recently including most notably GSK126 (McCabe et al.,
2012b) and EPZ005687 (Knutson et al., 2012) and EI1 (Qi et al.,
2012). These inhibitors act in a S-adenosylmethionine (SAM)
competitive manner with no effects on expression of components
of PRC2 or other histone methyl marks. This characteristic of
the newly developed inhibitors allows to distinguish the EZH2’s
methyltransferase-dependent and -independent function. In a
panel of B-cell lymphoma cell lines, EZH2 methyltransferase spe-
cific inhibitors are particularly sensitive in cells harboring muta-
tions in Y641 or A677 residue (McCabe et al., 2012b). Interestingly,
the cell line with A677 mutation appears to be most sensitive,
which correlates with the fact that A677 mutant efficiently catalyzes
all three steps of H3K27 methylation while Y641 mutant prefer-
entially enhance the reaction from di- to trimethylation (McCabe
et al., 2012a). In addition, it appears that loss-of-function muta-
tion in H3K27Me3 demethylase UTX may also confer sensitivity
to EZH2 inhibitors (McCabe et al., 2012b). However, gain-of-
function mutation is not sufficient to predict response to EZH2
inhibitors because certain cell lines with EZH2 mutation are not
sensitive to EZH2 inhibitors (McCabe et al., 2012b). Significantly,
EZH2 inhibitor GSK126 eradicated the growth of xenografted B-
cell lymphoma cells with EZH2 mutations (McCabe et al., 2012b).
Despite the fact that EZH2 is essential during development and is
known to regulate normal tissue stem cell properties, mice toler-
ated GSK126 very well with no apparent toxicity (McCabe et al.,
2012b). Together, these findings suggest that EZH2 inhibitors such
as GSK126 are potential novel epigenetic intervention reagents for
B-cell lymphoma harboring gain-of-function EZH2 mutations.
EZH2 inhibitors are equally effective in decreasing H3K27Me3
in cancer cell lines with wild type EZH2 compared with those with
gain-of-function EZH2 mutations (Knutson et al., 2012; McCabe
et al., 2012b). However, cell lines with wild type EZH2 are typically
much less sensitive to GSK126 (McCabe et al., 2012b). This obser-
vation suggests that methyltransferase-independent function of
EZH2 also contributes to the malignant phenotypes observed
in EZH2 over-expressing cancer cells. Notably, EZH2 is over-
expressed but not mutated in EOC. In addition, inhibition of
PRC2 by knockdown EZH2 (Li et al., 2010) or SUZ12 (Li et al.,
2012b) is effective in inhibiting the growth of EOC cells with over-
expressed components of PRC2. Therefore, it will be critical to
evaluate the effectiveness of EZH2 inhibitors in preclinical mod-
els for their effects on EOC cell growth as well as EOC-associated
angiogenesis. In addition to inhibiting EZH2’s methyltransferase
activity, targeting the PRC2 complex formation, or the associated
factors that affect PRC2 genome-wide distribution may represent
an alternative strategy for targeting PRC2 in EOCs. Further, given
the evidence that EZH2 target genes may also subject to other
epigenetic silencing mechanisms (Van der Vlag and Otte, 1999;
Nakamura et al., 2008), it will be interesting to examine whether
there are synergies between EZH2 inhibitors and inhibitors of
other epigenetic silencers such as HDAC and DNA methyltrans-
ferase inhibitors. Finally, given its potential role in conferring
chemotherapy resistance (Knutson et al., 2012; McCabe et al.,
2012b; Qi et al., 2012), it will be interesting to determine whether
EZH2 inhibitors re-sensitize chemo-resistant EOC cells.
CONCLUSION AND PERSPECTIVE
In summary, EZH2 and other components of PRC2 are often
over-expressed in EOC cells (Li et al., 2010, 2012b) and
EOC-associated endothelial cells (Lu et al., 2010). EZH2/PRC2
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promotes proliferation, suppresses apoptosis and increases
invasion potential of EOC cells (Li et al., 2010), and enhances
angiogenesis of EOC-associated endothelial cells (Lu et al., 2010).
The expression pattern and functional importance of EZH2/PRC2
establish it as an exciting target for developing new EOC thera-
peutics. Thus, it will very interesting to test the newly developed
EZH2 inhibitors in relevant preclinical in vitro and in vivo mod-
els. In addition to H3K27 residue, EZH2 can also methylate other
proteins. For example, EZH2 methylates an orphan nuclear recep-
tor RORa (Lee et al., 2012). Further, EZH2/PRC2 may also have
methyltransferase-independent function. Indeed, EZH2 is present
in both cytoplasm and nuclei and cytoplasmic EZH2 has been
shown to regulate actin polymerization and cell signaling (Su
et al., 2005). Accordingly, a further understanding the mecha-
nisms by which EZH2/PRC2 promote EOC will provide scientific
rationale for developing inhibitors of EZH2/PRC2 as novel EOC
therapeutics.
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